The international consensus process on psychopharmacology and intellectual disability.
The present authors invited 115 scientists, practitioners and consumers from 11 nations to form an international consensus panel on best practices and clinical effects regarding psychoactive medicines and intellectual disability. Co-sponsors included the American Association on Mental Retardation, the American Psychiatric Association, the American Psychological Association, the National Institute of Mental Health, the National Association on Dual Diagnosis and The Arc of the United States. The panel developed 21 reports that were revised to reflect comments from 351 participants at a 1995 Ohio State University conference in Columbus, OH, USA. The reports will be published as chapters in a forthcoming book entitled Psychotropic Medication and Developmental Disabilities: The International Consensus Handbook. The need for research and training programmes is discussed.
Reiss
S
S
Ohio State University Nisonger Center, Columbus 43210-1296, USA.
Aman
M G
MG
D003951:Diagnostic Errors; D006801:Humans; D008607:Intellectual Disability / Q000150:complications* / Q000175:diagnosis; D001523:Mental Disorders / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D010372:Pediatrics / Q000193:education; D011570:Psychiatry / Q000193:education; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*
D011619:Psychotropic Drugs